State-level access pathways won't cannibalize clinical trials for patients. Instead they could solve biotech's in-human data catch-22, and restore patient trust along the way.
Niklas Anzinger
Advertisement
Niklas Anzinger is CEO and founder of Infinita.
Articles by Niklas Anzinger
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
4
Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration
5